()
 

Overview

Since 2006, Alpharma has purchased vancomycin from Hisun pending the completion of the construction and regulatory approval process of a new Vancomycin manufacturing plant at the Hisun facility in China. The new facility, which will be owned and operated by Alpharma, will incorporate certain technology purchased from Hisun, in addition to certain Alpharma technology. Construction of the new facility is expected to be completed in early 2008, and Alpharma (Taizhou) Pharmaceutical Co., Ltd. is targeting to secure the necessary regulatory approvals to enable vancomycin produced at the new site to be sold in the global market place in 2008, including the U.S. and European markets.

Contact Information

One Executive Drive
Fort Lee, NJ 07024

tel: 908-566-3800
fax: 201-947-5541
http://www.alpharma.com

,  



Investor Relations



tel:
fax:




Stock

Exchange: NYSE
Industry: Drug Manufacturers - Other
Market Cap: $1.1B




 
The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.